Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LFCR Stock Forecast 2025-2026
$6.71
Current Price
$248.44M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to LFCR Price Targets
+49.0%
To High Target of $10.00
+49.0%
To Median Target of $10.00
+49.0%
To Low Target of $10.00
LFCR Price Momentum
-1.8%
1 Week Change
0.0%
1 Month Change
+37.2%
1 Year Change
-9.7%
Year-to-Date Change
-16.0%
From 52W High of $7.99
+82.3%
From 52W Low of $3.68
📊 TOP ANALYST CALLS
Did LFCR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lifecore Biomedical is one of their latest high-conviction picks.
Latest LFCR Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, LFCR has a bullish consensus with a median price target of $10.00 (ranging from $10.00 to $10.00). Currently trading at $6.71, the median forecast implies a 49.0% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Hewitt at Craig-Hallum, projecting a 49.0% upside. Conversely, the most conservative target is provided by Matthew Hewitt at Craig-Hallum, suggesting a 49.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LFCR Analyst Ratings
2
Buy
1
Hold
0
Sell
LFCR Price Target Range
Low
$10.00
Average
$10.00
High
$10.00
Current: $6.71
Latest LFCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LFCR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2025 | William Blair | Max Smock | Outperform | Initiates | $0.00 |
| Jan 3, 2025 | Stephens & Co. | Jacob Johnson | Equal-Weight | Reiterates | $6.00 |
| Nov 22, 2024 | Craig-Hallum | Matthew Hewitt | Buy | Maintains | $10.00 |
| Sep 5, 2024 | Craig-Hallum | Matthew Hewitt | Buy | Initiates | $8.00 |
| Aug 28, 2024 | Barrington Research | Michael Petusky | Market Perform | Downgrade | $0.00 |
| Sep 1, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $10.00 |
| Sep 1, 2023 | Stephens & Co. | Jacob Johnson | Equal-Weight | Maintains | $9.00 |
| Jun 2, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $11.00 |
| May 24, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $10.00 |
| Mar 21, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $8.00 |
| Mar 20, 2023 | Stephens & Co. | Jacob Johnson | Equal-Weight | Downgrade | $2.00 |
| Mar 20, 2023 | Barrington Research | Michael Petusky | Outperform | Maintains | $8.00 |
| Mar 17, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $11.00 |
| Dec 9, 2022 | UBS | Neutral | Maintains | $0.00 | |
| Dec 9, 2022 | Baird | Outperform | Maintains | $0.00 | |
| Dec 9, 2022 | Wells Fargo | Equal-Weight | Maintains | $0.00 | |
| Dec 9, 2022 | Piper Sandler | Overweight | Maintains | $0.00 | |
| Dec 9, 2022 | Morgan Stanley | Overweight | Maintains | $0.00 | |
| Dec 9, 2022 | Goldman Sachs | Buy | Maintains | $0.00 | |
| Dec 6, 2022 | Raymond James | Strong Buy | Maintains | $0.00 |
Lifecore Biomedical Inc. (LFCR) Competitors
The following stocks are similar to Lifecore Biomedical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lifecore Biomedical Inc. (LFCR) Financial Data
Lifecore Biomedical Inc. has a market capitalization of $248.44M with a P/E ratio of 56.2x. The company generates $130.31M in trailing twelve-month revenue with a -34.3% profit margin.
Revenue growth is -1.5% quarter-over-quarter, while maintaining an operating margin of -6.5% and return on equity of -83.6%.
Valuation Metrics
Market Cap
$248.44M
Enterprise Value
$422.26M
P/E Ratio
56.2x
PEG Ratio
-9.5x
Price/Sales
1.9x
Growth & Margins
Revenue Growth (YoY)
-1.5%
Gross Margin
+28.0%
Operating Margin
-6.5%
Net Margin
-34.3%
EPS Growth
-1.5%
Financial Health
Cash/Price Ratio
+2.2%
Current Ratio
2.7x
Debt/Equity
274.8x
ROE
-83.6%
ROA
-3.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lifecore Biomedical Inc. (LFCR) Business Model
About Lifecore Biomedical Inc.
What They Do
Develops and manufactures biomedical products.
Business Model
The company generates revenue through the production of high-quality hyaluronan and polysaccharide-based products tailored for medical applications. By serving diverse fields such as ophthalmology, orthopedics, and general surgery, Lifecore Biomedical Inc. leverages its expertise in manufacturing and formulation to integrate its biomaterials into drug delivery systems and surgical applications.
Additional Information
With a commitment to quality and innovation, Lifecore Biomedical Inc. plays a vital role in advancing medical technology, thus improving patient outcomes globally. Its strategic positioning within the biotechnology sector highlights its importance in the development of practical health applications and treatments.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
524
CEO
Mr. Paul Josephs
Country
United States
IPO Year
1996
Website
www.lifecore.comLifecore Biomedical Inc. (LFCR) Latest News & Analysis
Latest News
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors in Lifecore Biomedical (NASDAQ:LFCR) who purchased shares before October 7, 2020.
Why It Matters
The investigation into Lifecore Biomedical may indicate potential legal issues or financial mismanagement, impacting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Lifecore Biomedical (NASDAQ: LFCR) has secured a 10-year manufacturing and supply agreement with a significant existing customer, enhancing its CDMO operations.
Why It Matters
A 10-year agreement with a key customer signals revenue stability and growth potential for Lifecore Biomedical, positively influencing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lifecore Biomedical is restructuring as a CDMO with new management and improved finances. Potential for acquisition exists, possibly valuing LFCR at 2x current price, despite some risks.
Why It Matters
Lifecore Biomedical's restructuring, new management, and potential acquisition could double its valuation, appealing to investors seeking growth in a solid CDMO. Risks include capacity constraints and exit multiples.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Lifecore Biomedical, Inc. (NASDAQ:LFCR) who bought shares before October 7, 2020.
Why It Matters
The investigation into Lifecore Biomedical may indicate potential legal issues, affecting the company's stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Lifecore Biomedical (NASDAQ:LFCR) who purchased shares before October 7, 2020.
Why It Matters
Potential legal claims against Lifecore could signal financial instability or legal issues, impacting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
The company has strengthened its balance sheet and emphasized its commitment to disciplined capital management.
Why It Matters
A strengthened balance sheet indicates improved financial stability, potentially leading to better credit ratings and lower borrowing costs, enhancing overall investment attractiveness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LFCR Stock
What is Lifecore Biomedical Inc.'s (LFCR) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Lifecore Biomedical Inc. (LFCR) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $10.00.
Is LFCR stock a good investment in 2025?
According to current analyst ratings, LFCR has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LFCR stock?
Wall Street analysts predict LFCR stock could reach $10.00 in the next 12 months. This represents a 49.0% increase from the current price of $6.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lifecore Biomedical Inc.'s business model?
The company generates revenue through the production of high-quality hyaluronan and polysaccharide-based products tailored for medical applications. By serving diverse fields such as ophthalmology, orthopedics, and general surgery, Lifecore Biomedical Inc. leverages its expertise in manufacturing and formulation to integrate its biomaterials into drug delivery systems and surgical applications.
What is the highest forecasted price for LFCR Lifecore Biomedical Inc.?
The highest price target for LFCR is $10.00 from Matthew Hewitt at Craig-Hallum, which represents a 49.0% increase from the current price of $6.71.
What is the lowest forecasted price for LFCR Lifecore Biomedical Inc.?
The lowest price target for LFCR is $10.00 from Matthew Hewitt at Craig-Hallum, which represents a 49.0% increase from the current price of $6.71.
What is the overall LFCR consensus from analysts for Lifecore Biomedical Inc.?
The overall analyst consensus for LFCR is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are LFCR stock price projections?
Stock price projections, including those for Lifecore Biomedical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 6:40 AM UTC